Fiche centre
Atlanta Neuroscience Institute
Atlanta — United States
Essais liés6clinical trials
VilleAtlantalocalisation
PaysUnited Stateslocalisation
SourcelocaleCSV/MySQL
Informations
centreSynchronisé depuis ClinicalTrials.gov — NCT06553027
Essais cliniques associés
6| Molécule | Indication / population | Phase | NCT | Titre | Statut |
|---|---|---|---|---|---|
| Ocrelizumab | SEP | Phase 4 | NCT04377555 | Prospective Study to Assess Disease Activity and Biomarkers in Minority Participants With Relapsing Multiple Sclerosis (RMS) After Initiation and During Treatment With Ocrelizumab | COMPLETED |
| Ocrelizumab | SEP | Phase 3 | NCT05269004 | OLERO — A Rollover Study to Evaluate the Long-Term Safety and Efficacy of Ocrelizumab In Patients With Multiple Sclerosis | ACTIVE_NOT_RECRUITING |
| Ofatumumab approved dose | SEP | Phase 3 | NCT06869785 | FILIOS — Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of a New Maintenance Dosing Regimen of Ofatumumab | ACTIVE_NOT_RECRUITING |
| OCR SC | SEP | Phase 4 | NCT07609719 | OSSIA — A Study of Ocrelizumab Administered Subcutaneously in Participants With Multiple Sclerosis Who Switch From an Approved Anti-CD20 Therapy | RECRUITING |
| Interferon beta-1a | SEP | Phase 3 | NCT01412333 | A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple Sclerosis | COMPLETED |
| CVN424 75 mg | Parkinson | Phase 3 | NCT06553027 | To Evaluate the Efficacy of CVN424 in Parkinson's Disease Participants With Motor Complications | ACTIVE_NOT_RECRUITING |